Shanxi Buchang Pharmaceutical

Buchang Pharmaceuticals is one of China's largest integrated pharmaceutical groups specializing primarily in traditional Chinese medicines but also active across chemical drugs and biologics. It maintains a broad product portfolio spanning over six hundred marketed pharmaceuticals covering nearly every major therapeutic area relevant to public health needs within China—including cardiovascular disease where it holds significant market share through flagship brands like Danhong injection and Naoxintong capsules/granules. The group has expanded into innovative drug R&D through both internal efforts and M&A activity targeting new biological modalities while maintaining its core strength in herbal-based therapies approved by national regulatory authorities since the early/mid–2000s. Its headquarters are located in Xi'an with additional production bases throughout northern/eastern China regions including Shandong province—a key site for vaccine development/manufacture via its subsidiary network—and it remains independently operated following its successful IPO on the Shanghai Stock Exchange.